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1,2 Several mechanisms have been proposed to stimulate vasoconstriction in hypertension, including altered myocyte ion channel expression and function. 3 An increase in myocyte voltage-dependent Ca 2+ current density elevates intracellular Ca 2+ concentration, leading to vasoconstriction in hypertension. 4, 5 In hypertensive animal models, a reduction in expression and function of the β1 subunit of the large conductance Ca 2+ -activated K + (BK Ca ) channel increases vascular tone. 6, 7 Altered expression of several transient receptor potential (TRP) channels is also proposed to be associated with systemic and pulmonary hypertension. 8 However, molecular mechanisms by which alterations in TRP channel expression result in vasoconstriction in hypertension are poorly understood.
Many vasoconstrictors bind to phospholipase C-coupled receptors, leading to an elevation in inositol 1,4,5-trisphosphate (IP 3 ) that activates endo/sarcoplasmic reticulumlocalized IP 3 receptors (IP 3 Rs). 9 Three structurally and functionally distinct IP 3 R isoforms, designated IP 3 R1, IP 3 R2, and IP 3 R3, have been identified. 10 IP 3 R1 is the predominant molecular and functional isoform expressed in vascular myocytes. 10 Agonist-induced IP 3 R activation results in sarcoplasmic reticulum (SR) Ca 2+ release in cerebral artery myocytes that partially contributes to constriction. 10 Close spatial proximity of IP 3 R1 to plasma membrane canonical transient receptor potential 3 (TRPC3) channels also permits IP 3 to promote binding of the IP 3 R1 N terminus to the TRPC3 channel calmodulin and IP 3 R binding (CIRB) domain. 11 Isoform-selective physical coupling of IP 3 R1 to Abstract-Hypertension is associated with an elevation in agonist-induced vasoconstriction, but mechanisms involved require further investigation. Many vasoconstrictors bind to phospholipase C-coupled receptors, leading to an elevation in inositol 1,4,5-trisphosphate (IP 3 ) that activates sarcoplasmic reticulum IP 3 receptors. In cerebral artery myocytes, IP 3 receptors release sarcoplasmic reticulum Ca 2+ and can physically couple to canonical transient receptor potential 3 (TRPC3) channels in a caveolin-1-containing macromolecular complex, leading to cation current activation that stimulates vasoconstriction. Here, we investigated mechanisms by which IP 3 receptors control vascular contractility in systemic arteries and IP 3 R involvement in elevated agonist-induced vasoconstriction during hypertension. Total and plasma membrane-localized TRPC3 protein was ≈2.7-and 2-fold higher in mesenteric arteries of spontaneously hypertensive rats (SHRs) than in Wistar-Kyoto (WKY) rat controls, respectively. In contrast, IP 3 R1, TRPC1, TRPC6, and caveolin-1 expression was similar. TRPC3 expression was also similar in arteries of pre-SHRs and WKY rats. Control, IP 3 -induced and endothelin-1 (ET-1)-induced fluorescence resonance energy transfer between IP 3 R1 and TRPC3 was higher in SHR than WKY myocytes. IP 3 -induced cation current was ≈3-fold larger in SHR myocytes. Pyr3, a selective TRPC3 channel blocker, and calmodulin and IP 3 13 This physical coupling mechanism is essential for IP 3 -induced I Cat activation and a major contributor to agonist-induced constriction in cerebral arteries. 11, 12, 14 In contrast, mechanisms by which IP 3 Rs control systemic artery contractility are poorly understood, with contributions of SR Ca 2+ release and physical coupling of IP 3 Rs to TRP channels unclear. Similarly, whether pathological alterations in IP 3 R-mediated signaling contribute to elevated systemic vascular contractility during hypertension is poorly understood.
Here, we investigated physiological functions of IP 3 Rs in myocytes of mesenteric arteries. We also tested the associated hypothesis that molecular and functional alterations in IP 3 R signaling contribute to mesenteric artery vasoconstriction in hypertension. Our data indicate that IP 3 and endothelin-1 (ET-1) stimulate physical coupling of IP 3 R1 to TRPC3 channels, leading to I Cat activation in mesenteric artery myocytes and vasoconstriction. Data also indicate that hypertension is associated with an elevation in IP 3 -induced physical coupling of IP 3 R1 to TRPC3 channels, leading to vasoconstriction. In contrast, ET-1 does not induce vasoconstriction by stimulating SR Ca 2+ release in arteries of normotensive or hypertensive rats. In summary, our findings indicate that an elevation in IP 3 R1 to TRPC3 channel molecular coupling contributes to vasoconstriction during hypertension.
Materials and Methods
Expanded Materials and Methods are available at the online-only Data Supplement.
Results

IP 3 R1 Interacts With TRPC3 and Caveolin-1 in Mesenteric Arteries
IP 3 R1, TRPC3, and caveolin-1 (cav-1) are located in the same macromolecular complex and physically interact in cerebral artery myocytes. 12 Whether these proteins structurally organize in systemic arteries is unclear. Co-immunoprecipitation was used to examine whether IP 3 R1 associates with TRPC3 channels and cav-1 in Wistar-Kyoto (WKY) rat mesenteric arteries. A monoclonal mouse anti-IP 3 R1 antibody coimmunoprecipitated IP 3 R1, TRPC3, and cav-1 from WKY rat mesenteric artery lysate ( Figure 1 ). These data suggest that IP 3 R1, TRPC3 channels, and cav-1 exist in the same macromolecular complex in mesenteric arteries. 15 In contrast, at 12 weeks of age, WKY and SHR blood pressures (≈151 versus 217 mm Hg, respectively) are significantly different. 15 Western blotting indicated that TRPC3 protein was ≈2.7-fold higher in SHR (13-week) than in age-matched WKY rat mesenteric arteries ( To examine the hypothesis that hypertension is a factor associated with elevated vascular TRPC3 expression, protein was compared in 6-week-old pre-SHR and WKY rat arteries. TRPC3 protein was similar in 6-week-old SHR and WKY rat mesenteric arteries (Figure 2F and 2G; Figure S1 ). These data indicate that TRPC3 protein increases during the development of genetic hypertension, whereas TRPC1, TRPC6, IP 3 R1, and cav-1 expression remain unaltered in mesenteric arteries.
Hypertension Is
Plasma Membrane-Localized TRPC3 Channel Protein Is Elevated in SHR Arteries
Arterial surface biotinylation was performed to examine cellular distribution of TRPC3 channels in mesenteric arteries. Biotinylation indicated that ≈99.6% and 98.8% of total TRPC3 protein was present in the arterial plasma membrane in SHR and WKY rats, respectively ( Figure 3A and 3B). Surface TRPC3 protein was ≈2-fold higher in SHR than in WKY arteries ( Figure 3A and 3C). These data indicate that TRPC3 channels are predominantly membrane localized in mesenteric arteries. Furthermore, during hypertension the increase in TRPC3 channel expression directly translates to an elevation in plasma membrane TRPC3 protein.
Hypertension Is Associated With Increased Spatial Localization of TRPC3 Channels Nearby IP 3 R1 in Arterial Myocytes
Next, we investigated spatial proximity between arterial myocyte IP 3 R1 and TRPC3 in SHR and WKY mesenteric artery myocytes. Alexa 546-and 488-labeled secondary antibodies bound to primary antibodies targeting IP 3 R1 and TRPC3, respectively, produced mean N-FRET of ≈23.7% in isolated WKY rat arterial myocytes ( Figure 4A and 4B). In SHR myocytes, the same antibodies produced a higher mean N-FRET of ≈29.1% ( Figure 4A in mesenteric artery myocytes from 6-week-old pre-SHR and WKY rats. Baseline and the ET-1-stimulated elevation in mean N-FRET were similar in 6-week-old SHR and WKY myocytes ( Figure 4C ). These data indicate that TRPC3 is located in close spatial proximity to IP 3 R1, that IP 3 and ET-1 increase molecular localization between these proteins, and that hypertension is associated with an elevation in the spatial localization of TRPC3 channels to IP 3 R1 in mesenteric artery myocytes.
IP 3 Stimulates Larger Cation Currents in SHR Than WKY Myocytes
The significance of an elevation in TRPC3 channel expression and IP 3 R1 to TRPC3 molecular localization in SHR arterial myocytes was investigated by measuring IP3-induced cation current (I Cat ) using patch-clamp electrophysiology. Control I Cat density was similar in SHR and WKY arterial myocytes with mean values at ≈6 pA/pF at −120 mV ( Figure 5A and 5B). IP 3 increased mean I Cat density by ≈6 pA/pF in WKY myocytes and by ≈18 pA/pF in SHR myocytes, or ≈3-fold more (at −120 mV, Figure 5A and 5B). Pyr3, a selective TRPC3 channel blocker, 16 reduced IP 3 -induced I Cat in SHR and WKY rat arterial myocytes by ≈90% and 76%, respectively ( Figure 5A and 5B). CIRBP-TAT, a membrane-permeant peptide that blocks physical coupling of IP 3 Rs to TRPC channels, 11, 17 inhibited IP 3 -induced I Cat in SHR and WKY rat myocytes similar to Pyr3 (Figure 5A and 5B). These data indicate that IP 3 stimulates physical coupling of IP 3 R1 to TRPC3 channels, leading to I Cat activation in mesenteric artery myocytes. Data also reveal that augmentation of this coupling mechanism elevates IP 3 -induced TRPC3 currents in SHR myocytes during hypertension.
ET-1 Stimulates Larger Vasoconstriction Through an SR Ca 2+ Release-Independent Mechanism in SHR Mesenteric Arteries
The contribution of IP 3 Rs and TRPC channel activation to ET-1-induced mesenteric artery constriction was examined. ET-1 stimulated concentration (1-100 nmol/L)-dependent vasoconstriction in both WKY and SHR arteries. ET-1-induced vasoconstriction was larger at all concentrations studied, as was maximal force generation, in SHR arteries ( Figure 6A Figure S2 ; Figure 6B ). These findings indicate that ET-1-induced vasoconstriction occurs independently of SR Ca 2+ release in mesenteric arteries of both SHR and WKY rats and is larger in SHR arteries. Data also suggest that ET-1 sensitivity is similar in SHR and WKY arteries.
Pathological Vasoconstriction Occurs Because of an Elevation in Physical Coupling of IP 3 R1 to TRPC3 Channels in Myocytes
The functional significance of IP 3 R1 to TRPC3 channel physical coupling in mediating ET-1-induced vasoconstriction was Figure 6C ). Pyr3 and CIRBP-TAT did not alter baseline tension or depolarization-induced vasoconstriction, but both blockers inhibited ET-1-induced vasoconstriction ( Figures  S2 and S3 ; Figure 6C ). Importantly, Pyr3 more effectively blocked ET-1-induced constriction in SHR than in WKY arteries (≈83% versus 59% reduction, respectively; Figure  6C ). CIRB-TAT also attenuated ET-1-induced constriction more in SHR than in WKY arteries (≈57% versus 39% reduction, respectively; Figure 6C ). Taken together, these data indicate that an elevation in plasma membrane TRPC3 channels and physical coupling of these channels to IP 3 R1 in myocytes augment ET-1-induced vasoconstriction during hypertension.
Discussion
Here, we studied the functional significance of IP 3 Rs and TRPC3 channels to agonist-induced vasoconstriction in mesenteric arteries and the contribution of pathological alterations in IP 3 R-mediated signaling mechanisms during hypertension. Our data show for the first time that IP 3 R1 is located in close proximity to TRPC3 and is contained within a macromolecular complex containing TRPC3 and cav-1 in mesenteric arteries. Hypertension is associated with an increase in both total and plasma membrane TRPC3 protein and IP 3 R1 to TRPC3 spatial localization, leading to an elevation in IP 3 -induced I Cat in arterial myocytes. SR Ca 2+ release does not contribute to ET-1-induced vasoconstriction in mesenteric arteries of either normotensive or hypertensive rats, suggesting that IP 3 R activation stimulates vasoconstriction through alternate mechanisms. Our data indicate that physical coupling of IP 3 R1 to TRPC3 channels contributes to ET-1-induced vasoconstriction in mesenteric arteries and that enhancement of this mechanism contributes to the elevation in ET-1-induced vasoconstriction during hypertension.
TRPC3 expression is altered in several cell types in hypertension. TRPC3 mRNA and protein were elevated in lung tissues and pulmonary artery myocytes from patients with idiopathic pulmonary hypertension. 18 When compared with normotensive controls, TRPC3 protein was also higher in SHR and human monocytes, human renal arteriolar endothelium, kidney cortex of hypertensive Munich Wistar Frömter rats, and SHR aorta, mesenteric, carotid, and cerebral arteries. [19] [20] [21] [22] [23] [24] Our data indicating that TRPC3 protein is higher in mesenteric arteries of SHR than age-matched WKY rats are consistent with these results from other cell types. Mechanisms that elevate arterial myocyte TRPC3 channels in SHRs are unclear. Conceivably, the chronic elevation in blood pressure may stimulate transcriptional upregulation of TRPC3 channels. In addition, TRPC3 upregulation may be one mechanism that elevates systemic blood pressure. Functional and molecular alterations in IP 3 R1 and cav-1 also occur during hypertension. Pulmonary hypertension was associated with an elevation in pulmonary artery IP 3 R1 mRNA and protein, whereas IP 3 R1 expression was lower in renal medulla of SHRs than WKY rats. 25, 26 Although cav-1 knockout mice develop pulmonary hypertension, cav-1 protein was lower in SHR than in WKY rat aorta. 27, 28 Data from this and our previous study indicate that IP 3 R1, TRPC3, and cav-1 exist in a macromolecular signaling complex in both cerebral and mesenteric arteries. 12 Cav-1 and IP 3 R1 expressions were similar in SHR and WKY mesenteric arteries, suggesting that altered cav-1 and IP 3 R1 expression may be tissue dependent in hypertension. TRPC3, TRPC1, and TRPC6 channels regulate membrane potential, intracellular Ca 2+ concentration, and contractility in myocytes from a wide variety of different blood vessels. 29 Lower carotid artery and higher mesenteric arteriole TRPC1 protein has been reported in SHRs. 23, 24 TRPC6 protein was also higher in mesenteric artery myocytes of Milan hypertensive rats and ouabain-induced hypertensive rats than in normotensive controls. 30, 31 Our data indicate that TRPC1 and TRPC6 protein is similar in SHR and WKY rat mesenteric arteries. These contradictory data may result from differences in the arterial bed or animal models of hypertension studied.
Hypertension is associated with pathological alterations in vascular myocyte contractility, morphology, gene expression, and proliferation. 32 These changes may occur because of altered trafficking, cell surface expression, and spatial localization of signaling molecules, leading to dysregulation of physiological functions, including contractility. A proportion of TRPC3 protein is located intracellularly in a variety of cell types, including cerebral artery myocytes and cardiomyocytes. 11, 33 Data here show that essentially 100% of TRPC3 protein is located within the plasma membrane in mesenteric arteries, suggesting that TRPC3 distribution may differ depending on the cell type or anatomical origin of the vasculature. FRET experiments indicated that IP 3 R1 and TRPC3 channels are located in close spatial proximity and that ET-1 and IP 3 increase spatial proximity of these proteins in mesenteric artery myocytes, consistent with data in cerebral artery myocytes.
11,12 IP 3 R1 and TRPC3 antibodies generated a higher FRET signal in SHR myocytes that could originate from an increase in the number of TRPC3 channels nearby IP 3 R1 or from a reduction in the distance between TRPC3 and IP 3 R1, possibilities between which the FRET method cannot distinguish. Given that surface TRPC3 is higher and that IP 3 R1 and TRPC3 are already in such close spatial proximity to permit physical coupling, it is highly likely that the higher FRET signal occurs, at least in part, because of a larger number of TRPC3 channels nearby IP 3 R1.
ET-1 and uridine-5'-triphosphate activate an IP 3 R1-dependent TRPC3-mediated I Cat in cerebral artery myocytes. 13, 14, 34 Uridine-5'-triphosphate-induced whole cell currents were also larger in SHR carotid artery myocytes, although signaling mechanisms involved were not determined. 24 Here, data indicate that IP 3 stimulates physical coupling between IP 3 R1 and TRPC3 channels, leading to I Cat in mesenteric artery myocytes. IP 3 -induced I Cat density was larger in SHR than in WKY rat myocytes, likely attributable to an increased number of TRPC3 channels nearby IP 3 R1 and an elevation in functional coupling. This conclusion is supported by data indicating that Pyr3 and CIRBP-TAT essentially abolished IP 3 -induced I Cat in both WKY and SHR myocytes. These data also indicate that hypertension is not associated with the induction of promiscuous coupling of IP 3 Rs to November 2012 TRP channels other than C3, a potential mechanism that may have also elevated I Cat .
Small arteries from hypertensive humans and rats generate higher spontaneous tone and constrict more in response to receptor agonists. 1, 2, 24, [35] [36] [37] [38] [39] Here, although ET-1 and membrane depolarization stimulated larger vasoconstriction in SHR arteries, ET-1 sensitivity was similar, consistent with previous studies in perfused mesenteric arteries. 40, 41 When combined with other findings in this study, these data suggest that ET-1 stimulates larger vasoconstriction, in part, through stimulating more effective IP 3 R1-TRPC3 physical coupling in myocytes of hypertensive rats. This leads to larger I Cat , membrane depolarization, voltage-dependent Ca 2+ channel activation, and vasoconstriction. Our data also indicate that SR Ca 2+ release does not contribute to ET-1-induced vasoconstriction in either SHR or WKY mesenteric arteries, supporting the concept that physical coupling to TRPC3 channels is a primary mechanism by which IP 3 Rs stimulate vasoconstriction in mesenteric arteries. Data also show that IP 3 Rs and TRPC3 channels do not contribute to depolarization-induced vasoconstriction and that 2-aminoethoxydiphenyl borate, Pyr3, and CIRBP-TAT do not block voltage-dependent Ca 2+ channels, which elicit this response. Many vasoconstrictors, including angiotensin II and epinephrine, bind to phospholipase C-coupled receptors, leading to an elevation in intracellular IP 3 in smooth muscle cells. Therefore, our study also raises the possibility that other agonists may induce vasoconstriction by stimulating IP 3 R1 to TRPC3 coupling and that this mechanism may contribute to elevated contractility during hypertension.
In summary, data indicate that IP 3 R1 stimulates vasoconstriction primarily through physical coupling to TRPC3 channels in mesenteric artery myocytes. We also demonstrate that genetic hypertension is associated with an increase in TRPC3 protein, TRPC3 channel cell surface expression, and enhanced physical coupling of TRPC3 to IP 3 R1 channels. This pathological alteration elevates ET-1-induced vasoconstriction in hypertension.
Perspectives
An elevation in vascular resistance is a hallmark of hypertension. 1, 2 Identifying mechanisms that underlie vasoconstriction in hypertension is essential to develop novel therapies to induce vasodilation. We show that IP 3 R1 physically and functionally couples to TRPC3 channels in mesenteric artery myocytes, similar to previous data in cerebral artery myocytes. 11 We also identify a novel mechanism by which enhanced molecular and functional coupling of TRPC3 channels to IP 3 R1 elevates arterial contractility in hypertension. An increase in TRPC3 channel protein, TRPC3 channel surface expression, and molecular localization of these channels nearby IP 3 R1 enhances physical and functional coupling of IP 3 R1 to TRPC3 in SHR mesenteric artery myocytes. This pathological alteration in IP 3 R1 to TRPC3 coupling augments agonist and IP 3 -induced I Cat in arterial myocytes and vasoconstriction in hypertension. Our study also provides evidence that interfering with physical and functional coupling between IP 3 R1 and TRPC3 channels may be a novel therapeutic strategy to induce vasodilation in hypertension.
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Materials and Methods
Tissue preparation and arterial myocyte isolation. Animal protocols used were reviewed and approved by the Animal Care and Use Committee at the University of Tennessee Health Science Center. Male (6 or 13 week old) Spontaneously Hypertensive Rats (SHR) and Wistar-Kyoto (WKY) rats were purchased from Taconic (Germantown, NY). Rats were euthanized by intraperitoneal injection of sodium pentobarbital (150 mg/kg bodyweight). The mesenteric arterial bed was removed from the abdominal cavity, and placed into oxygenated ice-cold (4°C) physiological saline solution (PSS) of the following composition (in mM): 112 NaCl, 4.8 KCl, 24 NaHCO 3 , 1.8 CaCl 2 , 1.2 MgSO 4 , 1.2 KH 2 PO 4 , and 10 glucose, which was gassed with 21 % O 2 -5 % CO 2 -74 % N 2 to pH 7.4. Third and fourth order mesenteric artery branches (150-250 m in diameter) were dissected and cleaned of adventitial connective tissue. Myocytes were enzymatically dissociated from mesenteric arteries using a method similar to that previously described (1) . Briefly, mesenteric arteries were placed into HEPES-buffered solution (in mM: 55 NaCl, 80 sodium glutamate, 5.6 KCl, 2 MgCl 2 , 10 HEPES, and 10 glucose; pH 7.3 with NaOH) containing 1 mg/ml papain, 1 mg/ml dithioerythreitol, and 1 mg/ml bovine serum albumin (BSA) for 25 min (at 37°C) and immediately transferred to isolation solution containing collagenase F (1 mg/ml), and H (0.5 mg/ml), 100 µM CaCl 2 and 1 mg/ml BSA for 8 min (at 37°C). Arteries were subsequently washed in ice-cold isolation solution and triturated using a fire-polished glass pasteur pipette to yield single myocytes.
Co-immunoprecipitation (Co-IP).
Co-IP was used to examine physical association between IP 3 R1, TRPC3, and cav-1 in mesenteric arteries, as previously described (2;3). Co-IP was performed using the Catch and Release co-IP kit (Millipore). Arteries collected from ~ 8 rats were used for each experiment. Protein lysate was harvested from mesenteric arteries using ice-cold immunoprecipitation lysis buffer (Pierce). Arterial lysate was incubated at 4 °C overnight with control mouse IgG or IP 3 R1 mouse monoclonal antibody (5 µg), affinity ligand and wash buffer in a spin column containing IP capture resin. Protein samples were subsequently eluted from the beads after several washes. Samples were then analyzed by Western blotting using specific antibodies against IP 3 R1, TRPC3, and cav-1.
Western blotting. Western Immunoblotting was performed as previously described (4;5). Briefly, mesenteric artery lysate protein concentrations were determined spectrophotometrically. Proteins were separated by 7.5% SDS-polyacrylamide gel electrophoresis and transferred onto nitrocellulose membranes using a Mini Trans Blot Cell (Bio-Rad, Hercules, CA). Membranes were then incubated with respective antibodies and developed using enhanced chemiluminescence (Thermo Scientific). Images were documented on Kodak In Vivo F Pro Imaging System (Carestream Molecular Imaging, Rochester, NY). Band intensity was determined using Quantity One software (BioRad).
Surface Biotinylation. Surface proteins were measured in intact mesenteric arteries using surface biotinylation technique (3;6). For each experiment, intact mesenteric arteries free of adipose and connective tissues were incubated for 1 h at room temperature in a 1 mg/ml mixture each of EZ-Link Sulfo-NHS-LC-LC-Biotin and EZ-Link Maleimide-PEG2-Biotin reagents (Thermo Scientific) in PBS pH 7.4. Unbound biotin was removed by quenching with PBS supplemented with 100 mmol/L glycine and excess removed by washing with PBS. Arteries were then homogenized in RIPA buffer (Sigma) and cellular debris removed by centrifugation. The total protein concentration of the supernatant was determined followed by pull down of biotinylated surface proteins using Avidin beads in spin columns (Thermo Scientific). Biotinylated proteins were eluted from Avidin beads by boiling in 1x SDS-buffer containing 2% 2-mercaptoethanol. Western blotting was used to quantify surface TRPC3 protein using rabbit polyclonal anti-TRPC3 (Abcam).
Immunofluorescence resonance energy transfer (immuno-FRET).
ImmunoFRET was used to measure spatial proximity between IP 3 R1 and TRPC3 channels in mesenteric artery myocytes, as we have previously done (2;3). Freshly isolated mesenteric artery myocytes were allowed to adhere to poly-Llysine coated coverslips. Cells were then fixed with 3.7% paraformaldehyde (PFA) in Phosphate-Buffered Saline (PBS) for 15 min. PFA-fixed cells were then washed three times with PBS and permeabilized with 0.1% triton X-100 for 1 min at room temperature. Following 1 h incubation in PBS containing 5% BSA, myocytes were treated for 1 h at 37ºC with primary antibodies: mouse monoclonal anti-IP 3 R1 and polyclonal anti-TRPC3, each at a dilution of 1:100 in PBS containing 5% BSA. After a wash and block with PBS containing 5% BSA, myocytes were incubated for 1 h at 37ºC with secondary antibodies: Alexa 546-and 488-labeled secondary antibodies bound to primary antibodies targeting IP 3 R1 and TRPC3, respectively. Following Fluorescence images were acquired using a Zeiss LSM Pascal laserscanning confocal microscope. Images were background-subtracted and N-FRET was calculated on a pixel-by-pixel basis for the entire image and in regions of interest (within the boundaries of the cell) using the Xia method (7) and Zeiss LSM FRET Macro tool version 2.5.
Patch-Clamp Electrophysiology. Patch-clamp electrophysiology was performed on isolated myocytes. Isolated myocytes were allowed to attach to a glass coverslip in the bottom of a chamber for ~ 15 min prior to experimentation. Membrane currents were measured using the patch-clamp technique (Axopatch 200B, Clampex 8.2). I Cat was measured using the conventional whole cell patch-clamp configuration, as we have done previously. . Current amplitude at -120 mV was analyzed offline using pClamp 9 (Molecular Devices).
Wire myography. Mesenteric artery segments (~250 µm diameter; ~ 1.5 mm long) were mounted on tungsten wires and equilibrated in physiological saline solution for ~ 45 min at 37 o C in a multi-channel wire myograph system (DMT A/S Aarhus, Denmark). Arterial rings were subjected to a resting tension of 10 mN and allowed to equilibrate for ~ 30 min prior to experimentation. Myograph chambers were continuously gassed with 21 % O 2 -5 % CO 2 -74 % N 2 . Data were acquired using LabChart software (ADInstruments).
Antibodies and Chemicals. Anti-TRPC3, -TRPC1, -cav-1, and -actin were purchased from Abcam. Anti-IP 3 R1 and -TRPC6 were purchased from Alomone. Alexa 546 and 488 were purchased from Invitrogen. Unless otherwise stated, all reagents were purchased from Sigma Chemical (St. Louis, MO). Papain was purchased from Worthington Biochemical (Lakewood, NJ) and 2,3,6-Tri-O-Butyryl-myoInositol 1,4,5-Trisphosphate-Hexakis(propionoxymethyl) Ester (Bt-IP 3 ) was purchased from SiChem (Bremen, Germany). CIRBP-TAT was synthesized by Molecular Resource Center, UTHSC (Memphis, TN).
Statistical Analysis. Data are expressed as mean  standard error of the mean. Statistical significance was calculated by using Student's t-tests for paired or unpaired data or ANOVA followed by StudentNewman-Keuls test for multiple data sets. Ec 50 values were determined by non-linear regression analysis using GraphPad Prism software (GraphPad Software, San Diego, CA). P<0.05 was considered significant. Figure S1 . Full Western blots illustrating TRPC3 protein expression in 6 and 13 week old SHR and WKY mesenteric arteries. 
Results
